Get the Stockscreener App
4.7819
2.92%
0.2619
Organogenesis Holdings Inc stock is traded at $4.7819, with a volume of 43,958.
It is up +2.92% in the last 24 hours and up +8.19% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$4.52
Open:
$4.59
24h Volume:
43,958
Relative Volume:
0.04
Market Cap:
$608.90M
Revenue:
$433.14M
Net Income/Loss:
$4.95M
P/E Ratio:
133.95
EPS:
0.0357
Net Cash Flow:
$6.55M
1W Performance:
+1.13%
1M Performance:
+8.19%
6M Performance:
+28.86%
1Y Performance:
+82.43%
1-Day Range:
$4.59
$4.80
1-Week Range:
$3.58
$4.715
52-Week Range:
$2.28
$6.71
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
4.80 | 570.84M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
ZTS
Zoetis Inc
|
148.47 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.46 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.49 | 41.52B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.35 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.97 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Cantor Fitzgerald maintains Overweight rating on Organogenesis stock By Investing.com - Investing.com South Africa
Market reaction to Organogenesis Holdings Inc.’s recent newsROI Focused Setup Screener With Exit Markers - Newser
Is Organogenesis Holdings Inc. reversing from oversold territoryFree Weekly Chart Analysis With Entry Advice - Newser
How to track smart money flows in Organogenesis Holdings Inc.Free Entry and Exit Strategy Optimizer Tool - Newser
Detecting support and resistance levels for Organogenesis Holdings Inc.Free Fast Entry High Potential Stock Alerts - Newser
Organogenesis Holdings Inc. shares fall 6.64% intraday after reporting second quarter earnings. - AInvest
Transcript : Organogenesis Holdings Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Organogenesis stock price target raised to $9 by Cantor Fitzgerald - Investing.com Nigeria
Earnings call transcript: Organogenesis Q2 2025 misses EPS forecast, stock steady - Investing.com
Organogenesis: Q2 Earnings Snapshot - Connecticut Post
Organogenesis Holdings Inc (ORGO) Q2 2025 Earnings Call Highlights: Navigating Market Uncertainties Amidst Strong Growth in Surgical and Sports Medicine Products. - AInvest
Organogenesis Holdings Reports Mixed Q2 2025 Results - TipRanks
Organogenesis Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Organogenesis Holdings Inc. stock entering bullish territoryStock Market Trend and Pattern Analysis - Newser
Organogenesis Amends Credit Agreement Amid Revenue Decline - TipRanks
Can you recover from losses in Organogenesis Holdings Inc.Free Alert Feed for Momentum Based Picks - Newser
Applying Elliott Wave Theory to Organogenesis Holdings Inc.Free Real-Time Market Sentiment Tracking Tool - Newser
Intraday pattern recognizer results for Organogenesis Holdings Inc.Entry Optimization Guide with Volume Analysis - Newser
What technical models suggest about Organogenesis Holdings Inc.’s comebackStable Profit Zone and Loss Control Analysis - Newser
Will a bounce in Organogenesis Holdings Inc. offer an exitWatchlist Generator for Smart Money Signals - Newser
Organogenesis Holdings (NASDAQ:ORGO) Shareholders Are Still up 82% Over 1 Year Despite Pulling Back 10% in the Past Week - 富途牛牛
Analyzing drawdowns of Organogenesis Holdings Inc. with statistical toolsReal-Time Investment Signal Forecast with AI - Newser
Momentum divergence signals in Organogenesis Holdings Inc. chartFree Long Hold Safe Return Strategy - Newser
Moving Average Trends for Organogenesis Holdings Inc. Stock: What They IndicateSummary of Trade Cycles in 5-Year Range - Newser
How many analysts rate Organogenesis Holdings Inc. as a “Buy”Capitalize on market momentum for maximum profit - Jammu Links News
Is Organogenesis Holdings Inc. a growth stock or a value stockInvest smarter with cutting-edge analytics - Jammu Links News
What is Organogenesis Holdings Inc. company’s growth strategyMaximize gains with data-driven stock picks - Jammu Links News
What are analysts’ price targets for Organogenesis Holdings Inc. in the next 12 monthsConsistently superior profits - Jammu Links News
Is Organogenesis Holdings Inc. stock overvalued or undervaluedDiscover stocks with explosive upside potential - Jammu Links News
What catalysts could drive Organogenesis Holdings Inc. stock higher in 2025Exceptional risk-adjusted gains - Jammu Links News
How does Organogenesis Holdings Inc. compare to its industry peersBuild a diversified portfolio for steady growth - Jammu Links News
What institutional investors are buying Organogenesis Holdings Inc. stockOutstanding growth strategies - Jammu Links News
What makes Organogenesis Holdings Inc. stock price move sharplyDiscover stocks with strong growth potential - Jammu Links News
How Organogenesis Holdings Inc. stock performs during market volatilityFree Proven Entry Plan With Low Risk Trade - Newser
Organogenesis Holdings Inc. Stock Support and Resistance Levels You Should KnowTechnical Reversal Setup with Risk Limits - Newser
Published on: 2025-08-02 00:04:21 - Newser
Why Organogenesis Holdings Inc. stock attracts strong analyst attentionWeekly Entry Signal Based Forecast Tool - Newser
What analysts say about Organogenesis Holdings Inc. stock outlookEntry Opportunity Screener with Confirmation - Newser
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organogenesis Holdings Inc Stock (ORGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Freedman Lori | Chief Admin. and Legal Officer |
Jun 04 '25 |
Buy |
2.82 |
100,863 |
284,716 |
695,058 |
| Freedman Lori | Chief Admin. and Legal Officer |
Jun 06 '25 |
Buy |
2.99 |
9,022 |
26,949 |
846,459 |
0.28%
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):